If you’re interested in GLP-1 medications but injections feel like a barrier, the new oral Wegovy GLP-1 pill offers a needle-free option. Here’s how oral GLP-1 medications work, who they’re for, what results to expect, and how they compare to injections.

What are GLP-1 pills?

GLP-1 pills are FDA-approved prescription medications that help support weight management by working on the same appetite, fullness, and blood sugar pathways as injectable GLP-1 medications.  

Today, GLP-1 pills fall into a few key groups:

• GLP-1 pills approved for weight management: This includes the Wegovy tablet (oral semaglutide), approved and available as of December 2025 for chronic weight management in adults who meet criteria.
• GLP-1 pills approved for diabetes: Rybelsus is an oral GLP-1 approved for type 2 diabetes and uses lower daily doses of semaglutide.
• GLP-1 pills in development: Several oral GLP-1 medications, including orforglipron, are in late-stage clinical trials, with FDA decisions expected in 2026.

How do oral GLP-1 medications work?

Oral GLP-1 medications work by copying the action of GLP-1, a hormone your body naturally releases after you eat, to help regulate appetite, fullness, and blood sugar.

The science behind the pill

GLP-1 pills act on the same pathways as injectable GLP-1 medications:

• They mimic the GLP-1 hormone your gut produces after meals.
• They slow stomach emptying, which helps you feel full longer.
• They reduce appetite signals in the brain, making it easier to eat smaller portions.
• They support blood sugar regulation, especially after meals.

Pill vs. injectable: Same mechanism, different delivery

Oral and injectable GLP-1 medications work the same way in the body, but they’re delivered differently:

• The pill uses a special formulation (SNAC) that allows the medication to be absorbed despite stomach acid. Only oral Wegovy has this special technology.  There is no generic version of oral GLP-1 pills.
• Pills are taken daily, while injections are taken weekly.
• In studies, results are similar to the injection for weight management. In clinical trials of the pill, people lost about 13.6% of their body weight over 64 weeks, on average. In trials of the once-weekly injection (semaglutide 2.4 mg), people lost an average of about 14.9% of their body weight over 68 weeks.

Disclaimer: Weight loss outcomes reported in clinical trials may differ from individual results. Individual results depend on factors including adherence, lifestyle modifications, and underlying health conditions.

What results can you expect from GLP-1 pills?

Clinical trials show that GLP-1 pills can lead to meaningful, sustained weight management when taken as prescribed and paired with healthy eating and movement.

In studies of high-dose oral semaglutide (25 mg):

• People lost about 13.6% of their body weight over 64 weeks on average.
• About 30% of participants lost an average of 20% or more of their starting body weight.

Weight change is only part of the picture. GLP-1 pills are also linked with improvements that support overall health:

• Lower blood pressure.
• Healthier cholesterol levels.
• Reduced cardiovascular risk in people who meet eligibility criteria.

5 things to know before starting a GLP-1 pill

1. You’ll take it on an empty stomach with 4oz of plain water. For GLP-1 pills, wait 30 minutes before eating, drinking, or taking other medications.
2. Results take time. In clinical trials of the Wegovy pill, weight loss typically continues to build over the first year of treatment, with the largest reductions usually seen around 64 weeks.
3. Side effects are similar to injectables. Nausea, constipation, and other gut symptoms are most common, especially early on. Side effects often improve over time, and not everyone experiences them.
4. It’s part of a bigger picture. Pills work best alongside nutrition changes and movement.
5. Insurance coverage varies. Check your plan.

Who's a good candidate for oral GLP-1 medications?

You could be a good candidate for oral GLP-1 medications if:

• You have a BMI of 30+ or a BMI of 27+ with a weight-related health condition.
• You prefer pills over injections.
• You haven’t seen the progress you want with nutrition and movement support alone.
• You’re looking for a long-term weight management option, as these medications are meant for ongoing treatment.

It’s possible that GLP-1 pills are not right for you if:

• You have severe gastrointestinal conditions.
• You’re pregnant, planning to become pregnant, or breastfeeding.
• You’d have trouble following the dosing instructions (for GLP-1 pills, this includes taking them on an empty stomach and waiting 30-minutes before eating).

Who should not take a GLP-1 pill?

GLP-1 pills aren’t right for everyone. You should not take a GLP-1 pill if you have a personal or family history of medullary thyroid cancer (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

If you have a known allergy to semaglutide or any ingredient in the medication, you also shouldn’t take a GLP-1 pill.

Your care team can help assess whether GLP-1 pills are right for you.

Side effects and how to manage them

Like any medication, oral GLP-1s can cause side effects, especially when you’re first starting or adjusting your dose. Most symptoms are mild, temporary, and related to how these medications slow down digestion.  

Though uncommon, if you experience any serious side effects, be sure to seek immediate medical attention.

Tips for managing side effects

Studies have shown that side effects are typically mild to moderate and often temporary, typically improving as your body adjusts to the medication.

A few steps can help:

• Stay well hydrated. Digestive side effects like nausea or diarrhea can lead to dehydration, which can make nausea feel worse. 
• Talk with your care team about ways to manage nausea, such as adjusting meal timing or food choices.
• Follow gradual dose increases as directed by your care team. Stepping up the dose slowly helps your body adapt and can reduce side effects over time.

Reach out to your care team right away if you notice any of the following:

• Nausea or vomiting that feels severe, won’t let up, or makes it hard to keep fluids down.
• Severe belly pain, especially if it doesn’t improve (this can be a sign of pancreatitis).
• Possible gallbladder symptoms include pain in the upper right of your abdomen, nausea after meals, fever, or yellowing of the skin or eyes.

Check in with your care team if side effects feel concerning and disruptive. You shouldn’t suffer in silence. The knownwell team can work with you to troubleshoot any symptoms that arise.

What to eat while taking GLP-1 pills

Gastrointestinal management guidelines suggest eating smaller, lighter meals with protein, fiber, healthy fats, and plenty of fluids. These choices often feel easier on your stomach and support weight management.

Protein at every meal helps protect muscle during weight management and helps you stay satisfied. Examples include Greek yogurt, scrambled eggs, cottage cheese, tofu, meat, chicken, or fish.

Fiber supports digestion and fullness. Examples include oatmeal, berries, lentil soup, cooked veggies, or a small serving of beans mixed into rice. 

Healthy fats can help you feel satisfied and support steadier energy. Examples include avocado, olives, nut butter, or olive oil.

Fluids help with tolerance, especially if you have nausea or diarrhea. Dehydration can make nausea feel worse. If drinking a lot at once feels tough, try small sips all day. Some of the most hydrating options include water, herbal tea, sparkling water, broth, or ice chips. 

GLP-1 pills work better with the right support

GLP-1 medications can reduce appetite, but they don’t build a new eating pattern on their own. Working with a registered dietitian helps you find realistic, satisfying meals that support long-term progress.

What knownwell offers:

• Physicians and clinicians who specialize in weight management and metabolic health.
• Registered dietitians for personalized nutrition guidance while taking GLP-1 pills. 
• FDA-approved medications prescribed and monitored by your care team.
• Compassionate, judgment-free support at every step.

This kind of integrated care helps you find what actually works for your body. 

Ready to get started?

• Virtual visits: Available from home in all 50 states
• In-person clinics: Boston area, Chicago, Dallas/Fort Worth, and Atlanta
• Insurance accepted: Most major plans offer coverage. See if we accept your insurance.

Book a visit with knownwell to find out if GLP-1 pills are right for you. Your care team will provide ongoing support to help you feel stronger, healthier, and more confident in your journey.

‍

Frequently asked questions

What’s the difference between GLP-1 pills and GLP-1 injections?

GLP-1 pills and GLP-1 injections work the same way in the body, but the way you take them is different. GLP-1 pills are taken daily and often have timing rules, while injections are taken weekly and usually offer more flexibility.

How much weight can I lose on GLP-1 pills?

The amount of weight you can lose on GLP-1 pills varies from person to person, but clinical trials of the pill show an average loss of about 13.6%  body weight over 64 weeks. Results depend on the medication, dose, and how long you stay on treatment.

Are GLP-1 pills covered by insurance?

GLP-1 pills are sometimes covered by insurance, but coverage depends on your plan. Your insurer may require a specific diagnosis, prior authorization, or formulary status. 

Can I take GLP-1 pills if I don’t have diabetes?

Yes, you can take GLP-1 pills if you don’t have diabetes, but you meet the BMI and health criteria for chronic weight management. Some oral GLP-1 medications are approved for weight management, while others are approved specifically for type 2 diabetes.

How long do I need to take GLP-1 medication?

GLP-1 medications are designed for long-term weight management, and most people stay on them as long as they continue to help and still fit their health goals. Your care team will check in regularly to reassess benefits, side effects, and next steps.

What happens if I stop taking my GLP-1 pill?

Stopping GLP‑1 pills often leads to weight regain because the medication only works while you’re taking it. This response is normal and reflects how appetite and fullness signals return to baseline. That’s why ongoing nutrition, movement, and medical support matter, whether you continue medication or not.

Are GLP-1 supplements the same as GLP-1 pills?

No, GLP-1 supplements are not the same as GLP-1 pills. Prescription GLP-1 pills are FDA-approved medications, while supplements are not regulated the same way and have not shown comparable results in clinical trials.

Do I need to follow a specific meal plan while taking GLP-1 medication?

No, you do not need to follow a specific meal plan while taking GLP-1 medication, but most people do well with simple, balanced meals. Prioritizing protein and fiber-rich foodscan help support your progress. 

A registered dietitian can help you tailor this to your preferences and side effects.

Can I drink coffee before taking my GLP-1 pill?

No, you cannot drink coffee before taking your GLP-1 pill. They must be taken on an empty stomach with a small amount (4oz) of water, followed by a 30-minute wait before coffee or any other drink, food, or medication.

What’s the difference between the Wegovy pill and Rybelsus?

The Wegovy pill and Rybelsus are the same medication with different names and indications. Both contain oral semaglutide. Rybelsus has been approved since 2019 for type 2 diabetes, while the Wegovy pill is FDA-approved specifically for chronic weight management.

Is there an obesity pill instead of an injection?

Yes, there is an obesity pill instead of an injection. GLP-1 pills are a daily prescription option for adults living with obesity who meet eligibility criteria and prefer a pill over weekly injections. 

Are GLP-1 pills considered an obesity drug?

Yes, GLP-1 pills are considered an obesity drug when prescribed for chronic weight management in adults who meet BMI and health criteria. They are intended for long-term use and work best when paired with nutrition guidance, movement, and regular medical follow-up.

‍

Source list

Buckley, S. T., Bækdal, T. A., Vegge, A., et al. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine, 10(467), eaar7047. doi:10.1126/scitranslmed.aar7047. Retrieved from https://pubmed.ncbi.nlm.nih.gov/30429357/

Choudhury, K. (2025, November 6). Eli Lilly expects US FDA approval for oral obesity drug in March 2026. Reuters. Retrieved from https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-expects-us-fda-approval-oral-obesity-drug-march-2026-2025-11-06/

DiNicolantonio, J. J., O'Keefe, J. H. (2022). Monounsaturated Fat vs Saturated Fat: Effects on Cardio-Metabolic Health and Obesity. Missouri Medicine, 119(1), 69-73. PMID: 36033137. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9312452/

Fitch, A., Gigliotti, L., Bays, H. E. (2025). Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions. Obesity Pillars, 16, 100205. doi:10.1016/j.obpill.2025.100205. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12475867/

Fornes, A., Huff, J., Pritchard, R. I., et al. (2022). Once-Weekly Semaglutide for Weight Management: A Clinical Review. Journal of Pharmacy Technology, 38(4), 239-246. doi:10.1177/87551225221092681. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9272494/

Gabe, M. B. N., Breitschaft, A., Knop, F. K., et al. (2024). Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. Diabetes, Obesity and Metabolism, 26(10), 4480-4489. doi:10.1111/dom.15802. Retrieved from https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.15802

Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., et al. (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. Journal of Clinical Medicine, 12(1), 145. doi:10.3390/jcm12010145. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9821052/

Gunning, K. (2020). Oral Semaglutide: Balancing Promising Therapeutics with Adverse Effects and Access Barriers. Journal of Managed Care & Specialty Pharmacy, 26(9), 1077-1080. doi:10.18553/jmcp.2020.26.9.1077. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10391108/

Kane, M. P., Triplitt, C. L., Solis-Herrera, C. D. (2021). Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists. American Journal of Health-System Pharmacy, 78(7), 556-567. doi:10.1093/ajhp/zxaa413. Retrieved from https://academic.oup.com/ajhp/article/78/7/556/6044728

Kommu, S., Whitfield, P. (2024). Semaglutide. In StatPearls [Internet]. StatPearls Publishing. Updated February 11, 2024. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK603723/

Krajnc, M., Kuhar, K., Koceva, A. (2025). Oral semaglutide for the treatment of obesity: A retrospective real-world study. Frontiers in Endocrinology, 16, 1593334. doi:10.3389/fendo.2025.1593334. Retrieved from https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1593334/full

Krishnanda, S. I., Christabelle, M., Yausep, O. E., et al. (2025). The Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients with Type 2 Diabetes: A Systematic Review. Journal of Clinical Medicine, 14(7), 2239. doi:10.3390/jcm14072239. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11990051/

Liu, X., Lu, C. A., Shih, Y. T., et al. (2025). Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans. JAMA Network Open, 8(8), e2529842. doi:10.1001/jamanetworkopen.2025.29842. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12397888/

Marassi, M., Fadini, G. P. (2025). Real-world Evidence on Oral Semaglutide for the Management of Type 2 Diabetes. A Narrative Review for Clinical Practice. Clinical Therapeutics, 47(1), 102-110. doi:10.1016/j.clinthera.2024.11.005. Retrieved from https://www.sciencedirect.com/science/article/pii/S0149291824003308

Morales, J., Shubrook, J. H., Skolnik, N. (2020). Practical guidance for use of oral semaglutide in primary care: a narrative review. Postgraduate Medicine, 132(7), 687-696. doi:10.1080/00325481.2020.1788340. Retrieved from https://www.tandfonline.com/doi/full/10.1080/00325481.2020.1788340

Mozaffarian, D., Agarwal, M., Aggarwal, M., et al. (2025). Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. American Journal of Lifestyle Medicine. doi:10.1177/15598276251344827. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12125019/

National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Semaglutide. In StatPearls [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK603723/

Novo Nordisk. (2019, September 20). FDA approves Rybelsus® (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes [Press release]. PR Newswire. Retrieved from https://www.prnewswire.com/news-releases/fda-approves-rybelsus-semaglutide-the-first-glp-1-analog-treatment-available-in-a-pill-for-adults-with-type-2-diabetes-300922438.html

Novo Nordisk. (2025, January 5). Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America [Press release]. Retrieved from https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916475

Novo Nordisk Inc. (2025). Rybelsus (semaglutide) tablets prescribing information. Plainsboro, NJ. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051Orig1s020,213051Orig1s021lbl.pdf

Novo Nordisk Inc. (2025). Wegovy (semaglutide) injection and tablets prescribing information. Plainsboro, NJ. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf

Office of Dietary Supplements, National Institutes of Health. (n.d.). Dietary Supplements for Weight Loss: Fact Sheet for Health Professionals. Retrieved from https://ods.od.nih.gov/factsheets/WeightLoss-HealthProfessional/

Salleh, S. N., Fairus, A. A. H., Zahary, M. N., et al. (2019). Unravelling the Effects of Soluble Dietary Fibre Supplementation on Energy Intake and Perceived Satiety in Healthy Adults: Evidence from Systematic Review and Meta-Analysis of Randomised-Controlled Trials. Foods, 8(1), 15. doi:10.3390/foods8010015. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC6352252/

Santulli, G. (2025). From needles to pills: oral GLP-1 therapy enters the obesity arena. Cardiovascular Diabetology and Endocrinology Reports, 11, 31. doi:10.1186/s40842-025-00245-5. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12498447/

Shah, M. Y., Mohammad, A., Samejo, R. B. A., et al. (2025). Weight Loss That Lasts: Reviewing the Long-Term Impact of GLP-1 Receptor Agonists. Cureus, 17(7), e88334. doi:10.7759/cureus.88334. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12361690/

Smits, M. M., Van Raalte, D. H. (2021). Safety of Semaglutide. Frontiers in Endocrinology, 12, 645563. doi:10.3389/fendo.2021.645563. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8294388/

Tamayo-Trujillo, R., Ruiz-Pozo, V. A., Cadena-Ullauri, S., et al. (2024). Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. Frontiers in Nutrition, 11, 1398059. doi:10.3389/fnut.2024.1398059. Retrieved from https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1398059/full

Taylor, K., Tripathi, A. K. (2025). Adult Dehydration. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK555956/

Van Hout, M., Forte, P., Jensen, T. B., et al. (2023). Effect of various dosing schedules on the pharmacokinetics of oral semaglutide: A randomised trial in healthy subjects. Clinical Pharmacokinetics, 62(4), 635-644. doi:10.1007/s40262-023-01223-9. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10023024/

Wharton, S., Bækkdal, T. A., Davies, M., et al. (2025). Oral Semaglutide 25 mg for Weight Management. New England Journal of Medicine. doi:10.1056/NEJMoa2500969. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2500969

Wharton, S., Davies, M., Dicker, D., et al. (2025). OASIS 4: Significant Weight Loss With Oral Semaglutide Comparable With High-Dose, SC Versions. American College of Cardiology. Retrieved from https://www.acc.org/latest-in-cardiology/journal-scans/2025/09/24/16/40/oasis-4

Zhou, J., Wang, F., Li, S. (2025). The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: A systematic review and meta-analysis. Frontiers in Endocrinology, 16, 1646956. doi:10.3389/fendo.2025.1646956. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12727569/